Responses
Clinical/translational cancer immunotherapy
Original research
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
Compose a Response to This Article
Other responses
No responses have been published for this article.
